G protein-coupled receptors (GPCRs) are key regulators of cell physiology and control processes ranging from glucose homeostasis to contractility of the heart. A major mechanism for the desensitization of activated GPCRs is their phosphorylation by GPCR kinases (GRKs).
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(although not in GRKs). Because of the high conservation of the ATP-binding site among of the ~500 kinases, the majority of small molecule kinase inhibitors target the ATP-binding site in a binding mode similar to that of ATP itself, generally resulting in inhibitors that lack selectivity (Bogoyevitch and Fairlie, 2007) . However, with the discovery of imatinib it became clear that the inactive conformation of a given kinase can be quite unique and therefore targeted to produce selective inhibitors (Breitenlechner et al., 2005a; Noble et al., 2004; Rabiller et al., 2010) .
Since the discovery of a linkage between the overexpression of GRK2 and heart failure, GRK2 has been considered a pharmaceutical target for the treatment of cardiovascular disease (Dorn, 2009 ). The first reported inhibitors of GRK2 were polyanionic compounds, such as heparin and dextran sulfate, that had nanomolar potencies, but were considerably nonselective (Benovic et al., 1989) . Other GRK2 inhibitors represent poor drug leads due to either their lack of potency, selectivity, or non-druglike properties (Benovic et al., 1990; Iino et al., 2002; Palczewski et al., 1990; Winstel et al., 2005) . For example, the natural product balanol is a potent inhibitor of GRK2, but is relatively nonselective among AGC kinases (Setyawan et al., 1999; Tesmer et al., 2010) .
Structural analysis of bovine GRK2 has led to several crystal structures including complexes with the heterotrimeric G proteins Gα q and Gβγ, and balanol (Lodowski et al., 2003b; Tesmer et al., 2005) . Comparison of the apoGRK2 structure with the balanol complex revealed that balanol stabilizes a slightly more closed conformation of the kinase domain (4° closure of the large lobe relative to the small lobe). However, an additional 16° rotation of the large lobe is still required to achieve what is expected to be the fully closed state. Subtle MOL #71522 6 conformational changes were also observed in the P-loop and αB-αC helices of the small lobe with residues moving up to 1.6 Å away from the active site to accommodate the ligand. Thus, balanol appears to recognize and stabilize a unique inactive conformation of GRK2 .
Recently, a class of heterocyclic compounds has been discovered by Takeda Pharmaceuticals (Takeda, 2007) that show therapeutic potential and exhibit higher selectively for GRK2 than balanol (Fig. 2) . To determine the mechanism of selectivity for these inhibitors, we cocrystallized two of the discovered compounds (CMPD103A and CMPD101) with the GRK2-Gβγ complex. We then tested whether GRK2 subfamily-specific residues in the P-loop and αB-αC loop region could contribute to the selectivity of these compounds for GRK2. However, converting these residues to their equivalents in GRK1 had only subtle effects on their potency. MOL #71522 8 columns. Formation of the complex was verified by SDS-PAGE, and the GRK2-Gβγ containing fractions were pooled and concentrated (Amicon Ultra 50 kDa; Millipore, Billercia, MA).
For co-crystallization of compounds with GRK2-Gβγ, CMPD103A and CMPD101 solubilized in 100% DMSO were added to the concentrated GRK2-Gβγ complex and incubated on ice for 30 min at a final concentration of 100 μM each (2% DMSO final). Crystals were grown at 4 °C by the hanging drop vapor diffusion method with crystals observable after 1 day. The best diffraction data for a GRK2·CMPD103A-Gβγ crystal was collected from crystals harvested from drops composed of 2 μL protein (10 mg/mL protein) mixed with 2 μL well solution (7% PEG3350, 100 mM MES pH 6.25, and 250 mM NaCl). The best data for GRK2·CMPD101-Gβγ was collected from crystals harvested from drops composed of 2 μL protein (10 mg/mL protein) mixed with 2 μL well solution (7% PEG3350, 200 mM NaCl, and 100 mM MES pH 5.25). For comparison, GRK2·ATP-Gβγ crystals were generated by adding 1 mM ATP to the initial GRK2-Gβγ complex and then crystallized using 1μL:1μL hanging drops with a well solution containing 9% PEG 3350, 200 mM NaCl, and 100 mM MES pH 6.5. All crystals were harvested into a cryoprotectant solution containing: 20 mM HEPES pH 8.0, 100 mM MES (at the well solution pH), 300 mm NaCl, 10 mM CHAPS, 5 mM MgCl 2 , 2 mM dithiothreitol (DTT), 9% PEG3350, 25% ethylene glycol, and either 100 μM CMPD103A, 100 μM CMPD101 (in 100% DMSO, final concentration 2% DMSO) or 1 mM ATP. 2% DMSO was added to the harvesting solution for the GRK2·ATP-Gβγ crystals.
Data Collection and Structure Determination. The GRK2-Gβγ complexes crystallized in space group C2 and data was collected at APS beamline 21 ID-G. The diffraction data for all This article has not been copyedited and formatted. The final version may differ from this version. three structures is strongly anisotropic with the highest resolution data extending in a direction bisecting the a* and c* axes of the crystals, as described previously (Lodowski et al., 2003a) , thus contributing to the poor crystallographic data and refinement statistics in the higher resolution data shells (Table 1) . Data was integrated and scaled using HKL2000 (Otwinowski and Minor, 1997) , and the structures were solved using molecular replacement with the original GRK2-Gβγ structure (PDB: 1OMW) (Lodowski et al., 2003b) as the starting model (REFMAC5). Models for the ligands were generated using Sketcher (CCP4 6.1) and PRODRG (Schuttelkopf and van Aalten, 2004) (http://davapc1.bioch.dundee.ac.uk/prodrg/). The ligand bound GRK2-Gβγ models were built using COOT (Emsley and Cowtan, 2004) , and refined using TLS and restrained refinement in REFMAC5 (Murshudov et al., 1997; Winn et al., 2001 ).
MolProbity (Chen et al., 2010) and PROCHECK (Laskowski et al., 1993) were used for structure validation.
Phosphorylation of Rhodopsin. Urea-washed bovine rod outer segments (bROS) were purified as previously described (Papermaster, 1982) . Steady-state kinetics were conducted using saturating concentrations of ATP (0.5 mM ATP + [γ 32 P-ATP]), 2-20 μM bROS, and 50 nM GRK in a buffer containing: 20 mM HEPES pH 8.0, 1 mM CHAPS, 5 mM MgCl 2 , and 2 mM DTT.
The reactions were carried out in a 96-well PCR plate. For inhibition assays, 5 μL of varying concentrations of compound were added to each well, followed by addition of 5 μL GRK, and then 5 μL of bROS (added in the dark). The plate was then allowed to equilibrate for at least 30 min. The reaction was initiated by the addition of 5 μL of ATP and exposure to light at room temperature (~25°C). The reaction was quenched after 5-10 min with the addition of 4 μL of SDS-PAGE loading buffer. Reactions were then analyzed by SDS-PAGE. The gels were dried This article has not been copyedited and formatted. The final version may differ from this version. (Mezzasalma et al., 2007) . GRK2 or GRK-variants (0.05 mg/mL -0.2 mg/mL) were incubated at saturating ligand concentrations and 100 μM ANS in a total volume of 10 μL in triplicate, using
ABgene 384-well PCR microtiter plates (Thermo-Fisher, Waltham, MA). Fluorescence was measured at increasing temperatures (4-85°C) in 1 °C intervals using a ThermoFluor 384-well plate reader (Johnson & Johnson, New Brunswick, NJ) . The fluorescence data was analyzed using ThermoFluor Acquire 3.0 software (default settings).
This article has not been copyedited and formatted. The final version may differ from this version. (Takeda, 2007) . For example, CMPD101 inhibits GRK2 with an IC 50 of 35 nM, but > 2 µM for other tested kinases. However, the selectivity for members of the GRK family was not reported.
We therefore tested the activity of balanol in phosphorylation assays against bovine GRK1 535 -H 6 (GRK1), bovine GRK2-H 6 (GRK2), and bovine GRK5 561 -H 6 (GRK5) using bovine rod outer segments (bROS) as the receptor substrate and ATP at saturating concentrations (0.5 mM).
Balanol had an IC 50 of 35 nM for GRK2 (Fig. 3A , Table 2 ), similar to previously reported values . However, balanol was a less potent inhibitor of GRK5 and GRK1 (IC 50 values of 440 nM and 4.1 μM, respectively), than previously reported ), most likely due to different assay conditions (e.g. the soluble substrate tubulin and 3 µM ATP were used as substrates). Regardless, the selectivity order is the same (GRK2>GRK5>GRK1). We then tested CMPD103A and CMPD101 for their ability to inhibit bROS phosphorylation by GRK2, which yielded IC 50 values of 54 nM and 290 nM, respectively (Fig. 3B , Table 2 ). The IC 50 value for CMPD103A is similar to the reported IC 50 value for its parent compound (27 nM), however CMPD101 is 8-fold less potent than its reported value (Takeda, 2007) , with the difference again most likely due to different assay conditions. Neither CMPD103A nor CMPD101 inhibited GRK1 or GRK5 at any of the concentrations tested (up to 125 μM; Fig. 3C-D ). However, they did seem to increase the activity of GRK1 by up to 3-fold (see discussion).
To determine if the Takeda compounds are selective for GRK2 or instead for all members of the GRK2 subfamily, we tested CMPD101 against human GRK2 and human GRK3 in This article has not been copyedited and formatted. The final version may differ from this version. phosphorylation assays run under our previously reported assay conditions .
Under these conditions, CMPD101 inhibited GRK2 and GRK3 with IC 50 values of 54 nM and 32 nM, respectively (data not shown). Therefore, CMPD103A and CMPD101 are selective for the GRK2 subfamily, which is not surprising given that the primary sequences of their kinase domains are 92% identical.
X-Ray Crystal Structures.
To better understand how CMPD103A and CMPD101 achieve their selectivity, we co-crystallized these inhibitors with the GRK2-Gβγ complex and solved their atomic structures using diffraction data extending to 2.5 Å spacings. As a control, the GRK2-Gβγ complex was co-crystallized with ATP under similar conditions and the structure was solved using data to 2.7 Å spacings ( Table 1 ). The omit map for ATP revealed only weak electron density in the active site, as in the original GRK2-Gβγ structure (Lodowski et al., 2003b) , and hence it is referred to herein as the "ligand free" structure, or apoGRK2.
Both CMPD103A and CMPD101 bind deep in the active site of GRK2 and overlap extensively with the binding site for ATP (Fig. 4A,B ). The primary difference in their conformation is in their "D" rings, which are the most chemically divergent ( Fig The ATP-binding site is composed of several binding-pockets including the adenine, ribose, triphosphate, and hydrophobic subsites. The A rings of CMPD103A and CMPD101 bind in the adenine subsite and form a hydrogen bond between the pyridine/pyrimidine N4 atom of the A ring and the backbone amide nitrogen of Met274 in the hinge of the kinase domain (Fig. 5A ).
The ribose subsite is partially occupied by the B ring 1,2,4-triazole moiety ( Fig. 5B ), which sits deeper in the binding pocket than ribose and forms a hydrogen bond with the free amine of Lys220 and nonpolar interactions with the side chains of Ile197, Val205, Leu271, and Ser334.
The aryl C rings of CMPD103A and CMPD101 are positioned in the triphosphate subsite with the amino group forming hydrogen bonds with the side chains of Asp335 and Lys220. The carbonyl oxygen of the benzamide ring is positioned under the P-loop and is within hydrogen bond distance to the backbone amide nitrogens of Gly201, Phe202, and Gly203 (Fig. 5C ). The position and interactions of the benzamide ring in the active site are analogous to that formed by the structurally similar benzophenone ring of balanol . The D rings of CMPD103A and CMPD101 form nonpolar interactions with Gly201, Phe202, Leu235, Glu239, Gly337, and Leu338 in the hydrophobic subsite (also termed the "allosteric site") formed by the P-loop, the αB and αC helices, and the activation loop (Fig. 5D ).
Potential Determinants of Selectivity in the Inhibitor-Binding Site. The binding of balanol, CMPD103A, and CMPD101 induce very similar conformational changes in the active site of GRK2. However, our kinetic data indicates that CMPD103A and CMPD101 are much more selective towards GRK2 than balanol (Fig. 3) . Although residues that form the ATP-binding site This article has not been copyedited and formatted. The final version may differ from this version. are very well conserved among AGC kinases (Fig. 6) , analysis of our crystal structures indicated that five amino acids in the vicinity of the inhibitor-binding site could contribute to selectivity.
The P-loop undergoes significant conformational changes in our inhibitor bound structures, and Ile197, one of three non-conserved residues in the P-loop, makes a nonpolar contact with each inhibitor (Fig. 7A) . A direct contact is also formed by Leu235 in the hydrophobic subsite, whose side chain adopts a different rotamer than in the apoGRK2 structure in order to accommodate the D rings of CMPD103A and CMPD101 (Fig. 7B) . The equivalent residue is Gly in GRK1, and
Met in GRK4, -5, -6, and -7. Finally, the "gatekeeper residue", which sits at the back of the adenine subsite (Fig 5A) , is known to be a determinant of inhibitor specificity (Zuccotto et al., 2010) . In GRK2, the gatekeeper residue is Leu271, whose side chain contacts the A and B rings of the inhibitors and is not conserved in the GRK1 subfamily.
These five positions were mutated to their equivalents in GRK1 (I196V, I197L, Y206S, L235G, and L271M) to test if they reduced the affinity of the Takeda compounds. With the exception of the I196V mutant, which did not express, all were purified to homogeneity from baculovirusinfected insect cells. To test if these mutants produced functional protein, we determined the K M value of ATP for GRK1, 2, 5, and for each GRK2 mutant (Table 2) . If the mutants are correctly folded, they should not exhibit greatly different K M values, as all GRK active sites are optimized to bind ATP. GRK1 (Palczewski et al., 1988) , GRK2 (Kim et al., 1993) , and GRK5 (Kunapuli et al., 1994) We then tested the ability of balanol to inhibit the various GRK2 mutants (Fig. 8A , Table 2 ). The IC 50 values for balanol against the I197L, Y206S, and L235G mutations showed little difference from wild-type. The gatekeeper mutation L271M, however, increased the potency of balanol by 10-fold, which could reflect a reordering of amino acids around the hinge region that create more favorable hydrophobic contacts with the A ring of the inhibitor.
The P-loop mutations I197L and Y206S had no significant effect on the inhibition of GRK2 by CMPD103A or CMPD101 (Fig. 8B ,C, Table 2 ), whereas the L235G mutation in the αB-αC loop caused a 2-3 fold decrease in the potency of CMPD103A and CMPD101, indicating that the hydrophobic subsite in GRKs makes a small contribution to compound selectivity. The L271M mutation appeared to slightly increase the potency of CMPD103A and decrease the potency of CMPD101 (Fig. 8B ,C, Table 2 ). Although these latter observations are not statistically significant, they could be explained by the fact that the N2 atom of the A ring of CMPD103A, which is a pyrimidine, could be involved in a favorable electrostatic interaction with the sulfur atom of the substituted methionine. However, taken together our data demonstrates that the unique residues that compose the inhibitor-binding site in GRK2 do not strongly contribute to the affinity of the compounds, at least not when assessed by competition assays.
Ligand Induced Protein Stabilization. Compounds that bind to a native-protein will typically cause a stabilization of the protein to an extent that depends on the binding energy of the complex. This can be observed as a rightward shift in thermal denaturation curves. Native GRK2
has a melting temperature (T m ) of approximately 36 °C, and the addition of 500 μM ATP results in a 5 °C increase in its T m , indicating that ATP binds and stabilizes GRK2 (Table 3) . The
This article has not been copyedited and formatted. The final version may differ from this version. (Table 3 ). These ΔT m values are identical to the rank order of the potency of these compounds for inhibiting GRK2 activity (balanol>CMPD103A>CMPD101),
indicating that the thermal stability assay can be used to give valid comparisons of ligand affinity and is thus an orthogonal way to examine the selectivity of inhibitors.
GRK1 and GRK5 have melting temperatures of 25 and 29 °C, respectively, significantly lower than that of GRK2. Addition of 500 μM ATP stabilizes GRK1 and GRK5 by 17 and 7 °C, respectively, consistent with the observation that GRK1 has a significantly lower K M value for ATP than either GRK2 or GRK5, which exhibit smaller ΔT m values upon addition of ATP.
Addition of 100 µM balanol (10-fold higher than that added for GRK2) is less effective than ATP in stabilizing GRK1 and GRK5, with T m shifts of only 10 and 6 °C, respectively.
CMPD103A and CMPD101, also added at 100 µM, were even less effective with ΔT m values of 6 and 4 °C for GRK1, and 4 and 2 °C for GRK5, respectively. Thus, CMPD103A and CMPD101
can bind and stabilize both GRK1 and GRK5 under the ThermoFluor assay conditions at high ligand concentrations, yet are ineffective inhibitors of bROS phosphorylation under conditions of saturating ATP.
We next tested the GRK2 active site mutations for thermostabilization upon compound binding ( (Table 3) . However, the rank order of the ligands remains the same (balanol>CMPD103A>CMPD101) and correlates well with our IC 50 data (Table 2) . Thus, our data suggests that the identity of residues in the GRK active site have only modest effects on its affinity for inhibitors, and hence cannot explain the exquisite selectivity exhibited by the Takeda compounds for the GRK2 subfamily.
Structural Comparison with Inactive Conformations of GRK1 and GRK6
If the identity of individual amino acids in the vicinity of the inhibitor-binding site do not strongly contribute to selectivity among GRK subfamilies, then it seems likely that the inhibitors preferentially bind to a unique conformation exhibited by GRK2. A common trend among GRK crystal structures, excluding a GRK6·sangivamycin complex in which the kinase adopts a relatively closed state (Boguth et al., 2010) , is that the kinase domains assume relatively open, inactive conformations compared to the nucleotide-bound form of other AGC kinases. Moreover, these observed open states for GRK1, GRK2 and GRK6 are significantly different from each other (Singh et al., 2008) . We therefore modeled CMPD103A in the active site of these other GRK structures to assess if the inhibitors make less optimal interactions.
We first modeled CMPD103A into the apoGRK2 structure (Fig. 9A) , which, as expected, generated strong clashes between CMPD103A and the P-loop and αC-helix compared to the GRK2·CMPD103A structure (Fig. 9B ). This reflects repositioning of amino acids around the This article has not been copyedited and formatted. The final version may differ from this version. active site that takes place upon inhibitor binding. When docked into the GRK1 structure ( Fig.   9C ), CMPD103A clashes with multiple residues located in the P-loop, the β3-strand, and the activation loop. In the GRK6 structure (Fig. 9D ), CMPD103A clashes with multiple residues the P-loop, β3-strand, αC-helix, and activation loop. Thus, the GRK1 and GRK6 structures would need to adapt to accommodate the Takeda inhibitors. We ran our initial models/structures through a round of energy minimization using both REFMAC and the YASARA energy minimization server (Krieger et al., 2009 ) to alleviate the worst contacts, however in both cases the energy minimized models created worse contacts. Collectively, our biochemical data and modeling studies suggest that CMPD103A and CMPD101 bind to GRK2 in a unique conformation that enzymes in the GRK1 and GRK4 subfamilies cannot readily achieve.
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Discussion:
Crystal structures of protein kinases in complex with small molecules have provided valuable insights into how kinase inhibitors can achieve selectivity. Several mechanisms have been discovered, including the stabilization of a unique inactive conformation (e.g. imatinib/Gleevec) or targeting a less conserved hydrophobic pocket such as the one guarded by the "gatekeeper"
residue (e.g. erlotinib/Tarceva) (Sequist and Lynch, 2008) . In this study, we determined crystal structures of two highly selective inhibitors, CMPD103A and CMPD101, in complex with GRK2. These inhibitors bind GRK2 while it is in a relatively open, non-catalytic conformation, inducing 3.6° and 2.4° closures, respectively, relative to apoGRK2. CMPD103A and CMPD101
are markedly more selective than balanol, another potent inhibitor of GRK2 ). Balanol has a K i of 4 nM against PKA (Koide et al., 1995) and ~2 nM against bovine GRK2, whereas CMPD101 has IC 50 values of >2,000 nM and 35 nM for PKA and GRK2, respectively (Takeda, 2007) . A comparison of the PKA·balanol structure (Narayana et al., 1999) with that of GRK2·CMPD101-Gβγ suggests that the D ring of CMPD101 would collide with Phe187 of PKA in its hydrophobic subsite, thereby precluding binding. In fact, a F187L mutation in PKA, which would convert this residue to its equivalent in GRK2, was previously used to accommodate bulkier substituents to the D ring of a balanol analogue (Breitenlechner et al., 2005b) . Thus the identity of the residue at position 187 in PKA is likely a determinant for the selectivity of CMPD103A and CMPD101 versus PKA and related kinases.
CMPD103A and CMPD101 are also remarkably more selective among the GRK subfamilies than balanol, as these compounds can potently inhibit GRK2 and GRK3 mediated phosphorylation of bROS, but not GRK1 or GRK5 at the concentrations tested (Fig. 3) . If the This article has not been copyedited and formatted. The final version may differ from this version. (Narayana et al., 1999) . The C and D rings of the Takeda compounds have 5 less hydrogen bond donor/acceptor groups than balanol, which render them more reliant on complementary nonpolar interactions. This presumably renders them less able to adapt to the active sites of other GRK subfamilies.
Our data do provide evidence that CMPD103A and CMPD101 bind to members of other GRK subfamilies, albeit weakly and at much lower affinity than ATP, explaining why they are very poor competitive inhibitors. Both GRK1 and GRK5 exhibit 4-6 ˚C higher thermostability upon addition of 100 μM CMPD103A or CMPD101 (Table 3) . It was also observed that balanol, CMPD103A and CMPD101 increase the catalytic activity of GRK1 in our assays, although higher concentrations of inhibitor negate this effect (Fig. 3A,D) . This can potentially be explained by the low thermostability of GRK1 (T m = 25 °C), which is near room temperature, suggesting that GRK1 could aggregate and/or lose function during the course of our phosphorylation assays. The association of CMPD103A or CMPD101, although of low affinity, could stabilize GRK1 versus the controls and result in an apparent increase in catalytic activity.
Previous studies of other AGC kinases have indicated that residues in the active can significantly influence inhibitor selectivity. Conversion of amino acids in the active site of PKA to their This article has not been copyedited and formatted. The final version may differ from this version. equivalents in protein kinase B (PKB) conferred greater selectivity for balanol-like derivatives that preferentially inhibited PKB (Breitenlechner et al., 2005b) . In another study, residues in the P-loop, hinge region, and activation loop of PKA were converted to their equivalents in Rho kinase, and two mutants, T183A and L49I, (corresponding to Ser334 and Ile197 in GRK2) were shown to increase the affinity of Rho kinase-selective inhibitors for PKA (Bonn et al., 2006) .
Sequence alignment between the various GRK isoforms likewise reveals non-conserved residues in close proximity to bound CMPD103A and CMPD101 (Fig. 6) , with six of the 28 contacting residues differing. Out of these six residues, we hypothesized that three (Ile197, Leu235, and Leu271) could influence selectivity, with the other three residues left unexamined due to them having only backbone-mediated interactions with the inhibitors. In addition, we proposed that Ile196 and Try206 in the P-loop could indirectly play a role in selectivity as these residues undergo significant conformational changes upon ligand binding (Fig 7A) . However, when tested in phosphorylation assays against bROS, none of the mutations greatly altered the affinity for inhibitors, suggesting that the identity of the amino acids surrounding the binding site do not strongly contribute to selectivity among GRKs. This is in stark contrast to a previous studies in PKA, where the L49I mutation (corresponding to GRK2-I197L) decreased the affinity of the staurosporine like inhibitor KT5720 by ~180 fold (Bonn et al., 2006) .
Although it remains possible that multiple substitutions in GRK2, such as I197L in combination with I196V, are required to dictate significant changes in binding affinity for the Takeda inhibitors, it seems more likely that selectivity is dictated by the inactive conformation unique to GRK2. This mechanism is similar to that of the inhibitor imatinib, which is strongly selective for the inactive state of Abl over that of the closely related Src tyrosine kinase (Schindler et al., This article has not been copyedited and formatted. The final version may differ from this version. . The inactive states of these enzymes are dictated, at least in part, by distinct interactions between the kinase domain and the preceding SH2 and SH3 domains. Among GRK subfamilies, the N-terminal regulator of G protein signaling homology domain likewise interacts differentially with both the small and large lobes of the kinase domain, serving as a scaffold that likely helps to confer a unique kinase domain conformation. Consequently, the inactive states of GRK1 and GRK6 are not compatible with the Takeda compounds due to steric clashes in the active site (Fig. 9C,D) . For example, in the triphosphate subsite, substituents on the C rings of CMPD103A and CMPD101 are involved in a network of key hydrogen bonds between the activation loop (Asp335), β3-strand (Lys220), αC-helix (Glu239), and the P-loop (Fig. 5C ) that cannot be replicated in the crystal structures of GRK1 and GRK6.
In conclusion, our studies support the idea that small molecules selective for a particular GRK subfamily can be identified or designed, even when they bind in the active site of the kinase domain. This selectivity seems to be due primarily to the unique conformations of these enzymes in their inactive states. There are likely other families of compounds that have similar properties and that could likewise serve as future therapeutic leads to treat GRK-related diseases such as heart failure.
This article has not been copyedited and formatted. The final version may differ from this version. and CMPD101 are potential cardiotonic drugs discovered by Takeda Pharmaceutical Company (Takeda, 2007) . Balanol is a less selective AGC kinase inhibitor isolated from the fungus Verticillium balanoides (Koide et al., 1995) . Inhibition of GRK1, GRK2, and GRK5 activity by balanol. Modulation of (B) GRK2, (C) GRK5, and (D) GRK1 activity by CMPD103A, CMPD101, or the negative control DMSO. In panels (A) and (B), data is normalized to percent GRK2 and GRK5 activity based on a negative control containing no inhibitor and a positive control equivalent to background. The GRK1 data is normalized to the lowest concentration of balanol tested, due to the increase in activity versus This article has not been copyedited and formatted. The final version may differ from this version. GRK1-7 and bovine PKA were aligned using the ClustalW server (bovine GRK2, which was used in this study, has 100% identity in the kinase domain with that of human). Secondary structure is indicated by arrows for β strands and rectangles for α helices. Mutations listed along This article has not been copyedited and formatted. The final version may differ from this version. Representative curves from three or more separate experiments performed in duplicate are shown for each mutant and inhibitor. Data is normalized to percent GRK2 activity based on a negative control containing no inhibitor and a positive control equivalent to background. Dose-response curves were fit to either a 3 or 4 four-parameter model to determine IC 50 values (Table 2 ). This article has not been copyedited and formatted. The final version may differ from this version. 
